Nagi Bioscience offers an in vivo testing platform using microfluidic technology and nematode worms to provide rapid and cost-effective toxicity and efficacy assessments of substances. Their solution provides a faster and more ethical alternative to traditional animal testing methods.
Funding
$13.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IXSPFounders
Product
Problem
Traditional methods for assessing toxicity and efficacy of substances rely on animal testing, which is slow, expensive, and raises ethical concerns. These methods often lack the throughput and detailed data needed for rapid compound screening and analysis.
Solution
Nagi Bioscience offers an in vivo testing platform that utilizes microfluidic technology and C. elegans (nematode worms) to provide rapid, cost-effective, and ethical toxicity and efficacy assessments. Their Organism-on-Chip technology allows for high-content screening of drugs and chemicals using fully automated systems. The SydLab™ One platform enables precise control over the growth conditions of C. elegans, automated time-resolved treatment, and high-content analysis across their entire lifespan. This platform bridges the gap between in vitro research and clinical applications, providing relevant, full-organism data at the scale of in vitro testing.
Target Audience
Nagi Bioscience serves biopharma, biotech, academic research, agro-science, nutrition, nutraceutical, and cosmetic industries seeking faster, more efficient, and ethical biological testing solutions.
Features
- Patented Microfluidic Worm Matrices (MWM) technology for confining C. elegans within microfluidic chambers
- SydLab™ One platform for fully automated, high-content screening
- Nagi™ Chip L1-Sync and L4-Sync consumables for experiments with synchronized worm populations
- End-to-end contract laboratory solutions for aging, neurodegenerative, toxicity, compound efficacy, and microbiome studies
- Option for 16 independent biological conditions tested in parallel
- SydLab™ Analyzer software modules for data analysis